2006), phospholipase
, and RAC1/JUN NH(2)-1 terminal kinase (JNK) (Chiariello et al. 1998; Fukuda et al. 2002; Asai et al. 2006b ) are 2 activated by RET (Fig. 1) . In principle, gain-of-function of these pathways may 3 contribute to MTC. Moreover, negative regulators of RET signalling have also been 4 identified and, in principle, their loss-of-function may contribute to MTC formation 5 (Fig. 1) . 6
Hereafter, we focus on the RET pathways that have been more extensively 7 studied in MTC. Components of these pathways may be exploited as molecular targets 8 for MTC treatment. 9 10 RAS pathway  Growth factor binding to cell surface RTKs creates docking sites for 11 adaptor molecules that activate guanine nucleotide-exchange factors, which in turn 12 favours GTP binding to RAS small G-proteins (KRAS, HRAS and NRAS) (Schubbert 13 et al. 2007 ). Intrinsic RAS GTPase activity terminates signalling, a reaction that is 14 accelerated thousands of fold by GTPase-activating proteins (GAPs) such as 15 neurofibromin (NF1) ( Fig. 1) (Schubbert et al. 2007) . Once activated, RAS stimulates 16 numerous intracellular transducers, including RAF, phosphatidylinositol 3-kinase 17 (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS), to regulate 18 proliferation, survival and differentiation ( Fig. 1) (Halilovic & Solit 2008) . The RAS-19 >RAF->MEK->ERK cascade is the best characterized RAS effector pathway. There are 20 three RAF serine/threonine kinases (ARAF, BRAF and CRAF) that activate the MEK 21 (MEK1/MEK2) -> ERK (ERK1/2) kinase cascade. ERK (extracellular-signal regulated 22 kinase), in turn, stimulates gene transcription by directly phosphorylating transcription 23 factors or by targeting intracellular kinases like p90RSK ( Fig. 1) (Schubbert et al. 24 2007) . Negative regulators attenuate RAS signalling at various levels of the signalling 1 cascade ( Fig. 1) 
(see below). 2
RAS genes are most commonly activated by point mutations in cancer. 3
Alternatively, the RAS pathway can be triggered indirectly by loss of the negative 4 regulator NF1, by upstream activation of cell surface RTKs or PTPN11 (which encodes 5 the SHP-2 tyrosine-phosphatase) or by downstream activation of RAS signalling 6 effectors ( Fig. 1) (Wellbrock et al. 2004; Halilovic & Solit 2008) . This paradigm 7 applies to thyroid carcinoma of follicular cell lineage, where RET gene rearrangements 8 are prevalent in PTC, RAS mutations in follicular carcinoma (FTC) and in follicular-9 variant PTC (FV-PTC), and BRAF mutations in PTC and anaplastic carcinoma (ATC) 10 ( Kondo et al. 2006) . Sequencing analysis of all three RAS family members did not 11 reveal any mutation in about 30 MTC samples (Moley et al. 1991; Horie et al. 1995; 12 Bockhorn et al. 2000) . Similarly, no BRAF mutation was found in 65 MTC samples 13 (Xing 2005) . Taken together, these findings excluded that RAS/BRAF gene mutations 14 exert a prominent role in MTC formation. However, a recent study led to a different 15 conclusion by showing 41% KRAS mutations and 68% BRAF mutations in MTC 16 samples (Goutas et al. 2008) . 17
The degree and duration of activation dictate the final biological outcome of 18 RAS signalling. For example, in PC12 pheochromocytoma cells, transient RAS 19 activation stimulates proliferation, whereas sustained RAS activation induces 20 differentiation (Schubbert et al. 2007) . Similarly, oncogenic HRAS and CRAF alleles 21 decreased MTC cell proliferation and increased calcitonin gene expression (Nakagawa 22 et al. 1987; Carson-Walter et al. 1998) . Such a pro-differentiating effect of constitutive 23 RAS->RAF signalling may explain why mutations in these genes are unlikely to occur 24 in MTC. In this context, NRAS exerted a protective effect against MTC formation as 25
shown by the finding that NRAS deletion increased MTC formation in RB1-knock-out 1 mice (see also below) (Takahashi et al. 2006) . However, the role of RAS signalling in 2 MTC cells is probably complex and different components of the RAS family may exert 3 different effects. In fact, when targeted to C cells, an oncogenic HRAS mutant caused 4 MTC in transgenic mice (Johnston et al. 1998) . Similarly, MOS (Moloney murine 5 sarcoma virus oncogene), another oncogene that potently activates ERK, induced MTC 6 and pheochromocytoma in transgenic mice (Schulz et al. 1992) . With the caveat that 7 findings obtained in artificial animal models should be interpreted with caution, it is 8 conceivable that RAS signalling along the ERK cascade is involved mitogenic 9 signalling in MTC cells. In this context, it is noteworthy that inhibition of the ERK 10 pathway reduced proliferation of a RET mutant MTC cell line (Zatelli et al. 2005) . 11
Inhibitors of MEK are currently undergoing clinical experimentation in thyroid cancer 12 patients (Sherman 2008) . 13 14 Phosphatidylinositol 3-kinase (PI3K) pathway     Class I PI3K are constituted by a 15 regulatory (p85α, p55α, p50α, p85β, p55γ) and a catalytic (p110α, p110β, p110δ) 16 subunit. Upon recruitment to the plasma membrane by activated RTK or RAS, class I 17 PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to generate 18 phosphatidylinositol-3,4,5-triphosphate (PIP3) (Fig. 1) . PIP3, in turn, activates 19 downstream molecules such as the RAC small GTPase, 3-phosphoinositide-dependent 20 protein kinase 1 (PDK1), and the AKT (also known as PKB) serine/treonine kinase 21 (Yuan & Cantley 2008) . The lipid phosphatase PTEN (phosphatase and tensin 22 homologue deleted on chromosome 10) antagonizes this cascade by dephosphorylating 23 PIP3 (Salmena et al. 2008) . Besides buffering the PI3K pathway, PTEN also exerts 24 phosphatase-independent nuclear functions that may contribute to the potent oncogenic 25 effect resulting from its inactivation in tumours (Salmena et al. 2008) . AKT 1 phosphorylates and inactivates pro-apoptotic transcription factors of the FOXO 2 (Forkhead-Box Class O) family, the cell cycle inhibitor p27Kip1, and the GSK3β 3 kinase, thereby releasing β-catenin from the inhibitory effects of GSK3β (see below) 4 ( Fig. 1) (Yuan & Cantley 2008) . In addition, AKT stimulates the serine/threonine kinase 5 mTOR (mammalian target of rapamycin) (Fig. 1) . mTOR is associated with two 6 complexes: the rapamycin-sensitive TORC1 complex (that phosphorylates S6K to 7 regulate protein translation) and the rapamycin-insensitive TORC2 (which is the PDK2 8 activity that controls serine 473 phosphorylation of AKT itself) (Bjornsti & Houghton 9 2004). TORC1 also contributes to NF-κB activation (see below) ( Fig. 1) . 10
The PI3K->AKT->mTOR cascade is important in tumourigenesis because of its 11 ability to promote growth (cell size) and proliferation (cell number) and to prevent cell 12 death. Mutations in major nodes of this cascade are prevalent in human cancer and 13 include gain-of-function mutations and amplification of the genes encoding the catalytic 14 subunit p110α of PI3K (PIK3CA) and AKT (Zbuk & Eng 2007; Yuan & Cantley 2008) . 15
Mutations in this pathway are very frequent, for instance, in breast and colon cancer 16 (Wood et al. 2007) . Germ-line inactivating mutations of PTEN cause autosomal 17 dominant hamartoma syndromes, and somatic PTEN inactivation by deletion is very 18 frequent (up to 30%-50%) in sporadic tumours (Zbuk & Eng 2007; Paes & Ringel 19 2008) . Many studies have demonstrated that the PI3K->AKT system plays a key role in 20 RET signalling (Segouffin-Cariou et al. 2000; Kodama et al. 2005; Asai et al. 2006a) . 21
However, no systematic genetic analysis of PI3K pathway components has been 22 reported so far in MTC. PIK3CA gene amplification, which frequently occurs in 23 aggressive tumours of thyroid cells of follicular lineage, was not detected in 13 MTC 24 samples (Wu et al. 2005) . PTEN analysis in MTC has so far been limited to promoter 25 methylation assessment, and no methylation was detected in a small MTC set 1 (Schagdarsurengin et al. 2006) . However, C-cell hyperplasia and MTC occur in PTEN 2 heterozygous mice, particularly when crossed with mice knocked-out for CDKN2C 3 (encoding the p18INK4C cell cycle inhibitor) (see below) (Bai et al. 2006) . Thus, as 4 discussed for RAS, the PI3K->AKT cascade, even though infrequently mutated, may 5 play a role in MTC. Accordingly, in vitro chemical PI3K inhibition reduced MTC cell 6 proliferation and survival, which indicates that this pathway could be a molecular target 7 in MTC treatment (Kunnimalaiyaan et al. 2006a) . Given its central role in PI3K->AKT 8 signalling, and the availability of potent and selective inhibitors (everolimus, 9 temsirolimus) derived from rapamycin (sirolimus), mTOR is one of the most appealing 10 therapeutic targets in this pathway (Bjornsti & Houghton 2004) . 11 to MTC cell survival (Ludwig et al. 2001; Encinas et al. 2008) . 25
Recent studies have found mutations that directly target NF-κB pathway 1 components in human cancer (Wood et al. 2007) . A genetic analysis of the NF-κB 2 pathway in MTC has not yet been reported. Histochemical analysis of MTC tissue 3 samples revealed that many proteins of the NF-κB family, particularly p65, p52 and c-4
Rel, are localized in the nucleus (Gallel et al. 2008) . NF-κB inhibitors, particularly 5 IKK-β inhibitors, are being exploited in cancer therapy (Baud & Karin, 2009) . 6
Moreover, inhibitors of the 26S proteasome, such as bortezomib (Velcade), that prevent 7
IκB degradation and NF-κB nuclear translocation, exerted cytotoxic effects in MTC 8 cells (Mitsiades et al. 2006a) . 9 β-Catenin (CTNNB1)     β-Catenin, which is encoded by the CTNNB1 gene, plays an 11 important role in cellular adhesion by associating with E-cadherin and α-catenin. Upon 12 disassembling of the membrane complex, β-catenin migrates into the nucleus where it 13 acts as a co-activator of TCF/LEF (T-cell factor/lymphoid-enhancing factor) 14 transcriptional factors (Brembeck et al. 2006) . RET stimulates β-catenin activation via 15 direct phosphorylation on Y654 and via PI3K/AKT and RAS/ERK-mediated inhibition 16 of GSK3β (Fig. 1) (Gujral et al. 2008; Cassinelli et al. 2008; Castellone et al. 2009). 17 Although an analysis of the CTNNB1 gene in MTC has not yet been reported, MTC 18 samples from human patients and RET(M918T) transgenic mice showed nuclear β-19 catenin accumulation (Gujral et al. 2008) . The JAK->STAT pathway has been implicated in several neoplastic diseases, 25 particularly myeloproliferative disorders (Levine & Gilliland 2008) . Oncogenic RET 1 mutants induce serine phosphorylation through the RAS pathway, and tyrosine 2 phosphorylation of STAT3 ( Fig. 1) (Plaza Menacho et al. 2005; . Moreover, 3 activated STAT3 was identified in the nucleus of cells from MTC samples (Plaza 4 Menacho et al. 2005) . 5 6 Negative regulators of RET signalling  Several proteins function as feedback 7 regulators to attenuate RTK signalling and, intriguingly, the corresponding genes are 8 often downregulated in diverse tumour types (van Staveren et al. 2006; Amit et al. 9 2007) . Negative regulators of RET signalling have been identified. However, also in 10 this case, no systematic analysis of genetic alterations in MTC has yet been reported. 11
Below, we briefly discuss the effects exerted by tyrosine phosphatases (LAR, PTPRJ, 12 SHP-1), ERK dual-specificity phosphatases (DUSP) and RAS->BRAF signalling 13 inhibitors (SPRY) on RET signalling. 14 Tyrosine phosphatases de-phosphorylate RET and attenuate RET signalling; 15 theoretically, their loss could promote MTC formation (Fig. 1) . LAR (Leukocyte 16 common Antigen-Related) phosphatase (also called "PTPRF", protein tyrosine 17 phosphatase, receptor type, F) is a receptor tyrosine phosphatase that maps on a region 18 of chromosome 1 (1p) that is frequently lost in MTC (Mathew et al. 1987; Mulligan et 19 al. 1993) . LAR forms stable complexes with RET and de-phosphorylates RET cysteine 20 mutants (but not RET-M918T) thereby blunting cell proliferation (Qiao et al. 2001) . regulator of signalling systems. SHP-1 associates to RET, restrains RET 3 autophosphorylation, and inhibits MTC cell proliferation (Hennige et al. 2001; 4 Incoronato et al. 2004; Zatelli et al. 2005) . Intriguingly, SHP-1 is involved in the 5 cytostatic effects of somatostatin in MTC cells (Zatelli et al. 2005) . cascade. However, it should be noted that the pro-mitogenic and anti-mitogenic effects 14 of MKPs/DUSPs may vary depending on the specific complement of MAPK family 15 members they de-phosphorylate. For instance, DUSP4/MKP-2, which dephosphorylates 16 not only p42/44 MAPK (ERK) but also p38MAPK and JNK, exerts a positive (rather 17 than a negative) role in RET-mediated tumourigenesis and it is up-regulated in MTC 18 samples (Hasegawa et al. 2008) . 19 Sprouty (SPRY) and SPRED proteins are evolutionarily conserved inhibitors of 20 signalling that act by blocking RAS->RAF interaction and ERK activation. The 21 expression of SPRY family members is induced by RET, and SPRY2 blunted RET-> 22 ERK signalling (Ishida et al. 2007) . Intriguingly, genetic ablation of SPRY2 led to 23 enteric neuronal hyperplasia by promoting RET signalling (Taketomi et al. 2005) . 24
Similarly, SPRY1-deficient mice had kidney defects because of RET hypersignalling 25 (Gimm et al. 1999; 2001b) , NTRK2 expression was reduced, whereas NTRK3 17 expression was increased in MTC (McGregor et al. 1999) . Moreover, NTRK2 18 expression impaired the tumourigenicity of MTC cells (McGregor et al. 1999) . 19 Interaction between EGFR (epidermal growth factor receptor) and RET was recently 20 found to mediate EGFR-dependent RET activation (Croyle et al. 2008) . Phosphorylated 21 EGFR has been identified in MTC cells (Gorla et al. 2008) . It is noteworthy that 22
Vandetanib, a RET kinase inhibitor currently being investigated in MTC patients, is 23 also an EGFR inhibitor (Carlomagno et al. 2002) . No mutation in EGFR was found in 24 small MTC sample sets (Mitsiades et al. 2006b; Cerrato & Santoro unpublished) . 25
Fibroblast growth factor receptor-4 (FGFR-4) is expressed in aggressive thyroid tumour 1 types and MTC cells. Molecular targeting of FGFR-4 with an ATP-competitive 2 inhibitor prevented the growth and reduced the tumourigenesis of MTC cells (Ezzat et 3 al. 2005) . 4
Finally, membrane receptors of families other than the RTK family have been 5 implicated in MTC. NOTCH1 is a multifunctional transmembrane receptor that 6 regulates cell differentiation, development, proliferation and survival. Binding of 7 several ligands promotes proteolytic cleavage events, which result in the release of the 8 NOTCH1 intracellular domain that, in turn, translocates to the nucleus and activates 9 transcription of various target genes. NOTCH1 is a negative regulator of ASH1 10 (achaete-scute homolog-1, called "MASH1" in rodents), which is a highly conserved 11 basic helix-loop-helix transcription factor that is critical for C-cell development 12 (Lanigan et al. 1998) . Interestingly, MTC expresses ASH1 but not NOTCH1, and 13 NOTCH1 expression arrested proliferation of MTC cells (Kunnimalaiyaan et al. 14 2006b ). The prolactin receptor (PRLR) belongs to the cytokine receptor family and 15 activates the JAK->STAT pathway. Unexpectedly, PRLR-null mice developed MTC at 16 a high frequency, thereby suggesting that PRLR suppresses MTC formation at least in 17 mice (Kedzia et al. 2005) . 18
19

Tumour suppressors of the RB1 and TP53 pathways in MTC 20
The tumour suppressor genes RB1 (retinoblastoma: pRB protein) and TP53 (p53 21 protein) are frequently mutated in human cancer, and several lines of evidence indicate 22 that both pathways must be inactivated in cancer to overcome senescence or apoptosis 23 (Hahn & Weinberg 2002) . RB1 is the prototypic member of the class of tumour 24 suppressors known as "gatekeepers", which control tumour growth in a cell-autonomous 25 manner. This mainly depends on pRB's ability to repress the effect exerted by the 1 E2F/DP family of transcription factors, namely, stimulation of cell cycle progression or 2 apoptosis ( Fig. 2) (Hahn & Weinberg 2002) . Binding of the pRB protein to E2F/DP 3 transcription factors is high when pRB is hypophosphorylated in G1, and low when 4 pRB is hyperphosphorylated in S and G2 phases. pRB is phosphorylated sequentially by 5 D-, E-and A-type cyclin-mediated CDK activity. In turn, CDKs are negatively 6 regulated by CDK inhibitors (CKI) of the INK4 (p16INK4A, p15INK4B, p18INK4C, 7 p19INK4D) and CIP/KIP (p21CIP1, p27KIP1, p57KIP2) families (Fig. 2) . Tethering of 8 pRB to E2F target genes results in cell cycle arrest (Trimarchi & Lees 2002) . There are 9 multiple interactions between the pRB and the p53 pathways (Fig. 2) . On one hand, by 10 stimulating transcription of the p21CIP1 (CDKN1A) cell cycle inhibitor, p53 obstructs 11 the activity of cyclin E/CDK complexes, thereby reducing pRB phosphorylation and, 12 consequently, E2F activity. On the other hand, loss-of-function of pRB releases not only 13 the pro-mitogenic but also pro-apoptotic activity of E2F transcription factors. The final 14 outcome may depend on TP53 genetic status because E2F-mediated apoptosis is 15 dependent on the upregulation of p14ARF that in turn stabilizes p53. Therefore, in 16 cancer, RB1 and TP53 are often concurrently mutated (Hahn & Weinberg 2002) . 17
There is extensive genetic evidence in rodents that the pRB and p53 pathways 18 are involved in MTC. RB1-deficient mice developed MTC (Harrison et al. 1995) . 19
Conditional RB1 inactivation also induced highly aggressive MTC in mice 20 (Kucherlapati et al. 2006) . Loss of TP53 further increased MTC formation in RB1-21 deficient mice (Williams et al. 1994; Harvey et al. 1995) . E2F family transcription 22 factors exerted a dual role in MTC formation. Genetic deletion of E2F1 or E2F4 23 reduced MTC formation in RB1-deficient mice (Yamasaki et al. 1998; Lee et al. 2002) . 24
Instead, deletion of E2F3 further increased the incidence and aggressiveness of MTC 1 (Ziebold et al. 2003) . 2 Interestingly, MTC from RB1/TP53-deficient mice acquired somatic cysteine 3 mutations in RET that closely resemble activating mutations observed in human MTC. 4 This suggested that murine MTC requires mutational dysregulation within both the RET 5 and nuclear tumour suppressor gene pathways (Coxon et al. 1998) . High grade MTC 6 were observed in mice simultaneously lacking RB1 and CDKN1B (that codes for the 7 p27Kip1 cell cycle inhibitor) (Park et al. 1999) . Interestingly, germline mutation in 8 CDKN1B predisposed rats to a multiple endocrine neoplasia syndrome featuring MTC 9 formation (Pellegata et al. 2006) . In transgenic mice, the loss of two CDKIs, CDKN1B 10 and CDKN2C (coding for the p18INK4C cell cycle inhibitor), led to accelerated MTC 11 formation (Franklin et al. 2000; Joshi et al. 2007) . CDKN2C deficiency also accelerated 12 MTC formation in PTEN-deficient mice (Bai et al. 2006) . Finally, transgenic mice 13 expressing oncogenic RET crossed with mice lacking CDKN2C developed MTC at a 14 higher incidence and sooner than their single mutant littermates (van Veelen et al. 15 2008) . 16
Taken together, these studies provide robust evidence that, in rodents, disruption 17 of the RB1 and TP53 pathways predisposes to MTC formation. However, mice models 18 may not faithfully mimic the human situation, and the tumour spectrum may 19 significantly differ in the two species. A prominent example of this concept is provided 20 by the phenotype of RB1-deficient mice. In humans, loss of the RB1 gene is associated 21 with the development of retinoblastoma and osteosarcoma and, later in life, small-cell 22 lung carcinoma, whereas RB1-deleted mice do not develop these types of tumours, and 23 develop retinoblastoma only when the RB1-related RBL1 gene is concurrently deleted 24 (Rangarajan et al. 2003) . Early studies did not find TP53 mutations in sets of 9 25 JME-09-0024v2 Molecular genetics of MTC 22 (Yoshimoto et al. 1992) and 22 (Herfarth et al. 1997 ) MTC samples. More recent 1 studies identified a high prevalence of TP53 mutations (Pavelić et al. 2006) and 2 deletions in MTC (Sheikh et al. 2004) . Very recently, about 10% MTC were found to 3 carry loss-of-function mutations in CDKN2C (van Veelen et al. 2009 ); however, we did 4 not find any CDKN2C mutation in 15 MTC samples (Cerrato & Santoro unpublished) . 5 A systematic analysis of the genes in the RB1 and TP53 pathways in human samples 6 will help to clarify their role in MTC formation. Given the role played by these tumour 7 suppressor pathways in the response of tumours to therapy, this information might be 8 important for the analysis of data from the ongoing MTC trials involving the use of 9 targeted agents. 10 11
Conclusions 12
The identification of RET mutations has revolutionized the medical treatment of patients 13 with familial MTC. Twenty-five years after this seminal discovery, no other genetic 14 lesion has been consistently associated with MTC formation. Studies of the RET 15 pathway and mouse models of MTC formation are generating an ever-growing list of 16 genes, including the recently described CDKN2C gene (p18INK4C cell cycle inhibitor), 17 that could play a role in MTC. Biochemical data also indicate that these pathways play a 18 role in MTC formation. A thorough analysis of these genes has not yet been performed, 19
and the results of the few studies available, conducted, moreover, on a limited number 20 of samples, are often conflicting. An unbiased genome-wide analysis of sequence 21 variations, copy gains and losses will probably provide groundbreaking information as 22 has occurred for various tumour types (Sjöblom 2008) . It is expected that identification 23 of lesions in genes other than RET will clarify the biology of MTC and foster the 24 development of targeted therapeutic approaches. In any event, the data acquired in 25 recent years about the signalling mechanisms operating in MTC show that molecular 1 targeting of pathways like the RAS/ERK, PI3K/AKT and NF-kB pathways is a 2 plausible therapeutic approach for this cancer. 3
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